Patients with psoriasis may soon have another option in dermatological care thanks to a new oral treatment that has been developed by VBL Therapeutics. The pharmaceutical company has announced the initiation of a Phase 2 efficacy and safety study for an orally-administered immune response modifier that promises to reduce inflammation in the body that triggers psoriasis.
The Phase 2 study will involve approximately 180 patients with moderate to severe psoriasis, and will run for 12 weeks.
According to Dror Harats, M.D., chief executive officer of VBL Therapeutics, “The availability of a new oral therapy that is convenient, safe and effective would be an important treatment advance for patients with psoriasis…building on the promising results observed preclinically and the success of four separate Phase 1 clinical studies, we are excited to advance VB-201 into Phase 2 development for psoriasis. We look forward to launching clinical trials in additional indications in the near-term, as well as entering Phase 2 clinical development with VB-111, our lead oncology drug candidate.”
Psoriasis affects thousands of men and women in the United States and is a chronic immune disease that can become a severe burden physically and emotionally. The World Health Organization estimates that more than 125 million people suffer from psoriasis worldwide, and more than seven million patients in the United States have been diagnosed with the chronic skin condition.
The oral medication currently under evaluation is designed to counterbalance the body’s inflammatory response and improve immune system functioning so that the effects of psoriasis on the skin decrease naturally. The primary goal is to treat inflammation that is causing the skin problems, thereby improving the overall health of the skin.
The estimated market for psoriasis treatments is currently valued at more than $2 billion and is projected to rise more than $3 billion by 2011, according to a report in MedicalNewsToday.com.